Table 1 Clinical characteristics at hospital admission (V1).

From: Identification of novel blood biomarkers of treatment response in cystic fibrosis pulmonary exacerbations by label-free quantitative proteomics

Clinical characteristics
Number of PEx25
Number of subjects22
Age, mean (SD)34.8 (12.9)
Female, No. (%)12 (48)
Genotype, No. (%)
   ΔF508 Homozygous11 (50)
   \(\Delta \)F508 Heterozygous7 (32)
   Other (non-\(\Delta \)F508)4 (18)
FEV1% predicted, mean (SD)53.2 (20.7)
>10% relative drop FEV1% predicted from baseline, No. (%)a14 (56)
BMI, mean (SD)21.7 (3.5)
CFRSD-CRISS, mean (SD)50.5 (7.5)
Modified Fuchs Score, median (range)6 (4 to 8)
Best FEV1% predicted in 6 months prior to PEx, mean (SD)63.4 (21.5)
Best FEV1% predicted in 6 months prior to PEx, No. (%)
   <404 (16)
   40–6911 (44)
   70–894 (16)
   ≥906 (24)
Sputum Microbiology, No. (%)
   P. aeruginosa14 (56)
   MSSA12 (48)
   MRSA4 (16)
   Burkholderia cepacia complex3 (12)
Symptom Onset, No. (%)
   >2 weeks13 (52)
   <2 weeks12 (48)
  1. Abbreviation: PEx, pulmonary exacerbations; FEV1, forced expiratory volume in 1 second; BMI, body mass index; CFRSD-CRISS, CF Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score; P. aeruginosa, Pseudomonas aeruginosa; MSSA, Methicillin-sensitive S. aureus; MRSA, Methicillin-resistant S. aureus.
  2. aBaseline lung function is defined as the best FEV1% predicted in the 6 months prior to the index PEx.